Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
Date | Total number of shares | Total number of voting rights |
04/30/2025 | 136,948,872 | Total gross of voting rights: 136,948,872 |
Total net* of voting rights: 136,762,549 |
* Net total = total number of voting rights attached to shares – shares without voting rights
Last Trade: | US$10.83 |
Daily Change: | -0.16 -1.46 |
Daily Volume: | 2,574 |
Market Cap: | US$296.310M |
January 08, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load